Sophiris Bio Inc. (NASDAQ:SPHS) shares saw strong trading volume on Tuesday . 13,495,213 shares were traded during trading, an increase of 281% from the previous session’s volume of 3,544,283 shares.The stock last traded at $7.67 and had previously closed at $5.95.

Several research analysts have recently commented on the stock. Echelon Wealth Partners restated a “buy” rating and set a $5.00 price target on shares of Sophiris Bio in a research note on Friday, June 10th. Maxim Group restated a “buy” rating and set a $4.00 price target on shares of Sophiris Bio in a research note on Friday, June 10th.

The company has a 50-day moving average of $2.52 and a 200 day moving average of $1.77. The firm’s market cap is $117.40 million.

Sophiris Bio (NASDAQ:SPHS) last issued its quarterly earnings data on Monday, May 16th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.06. Equities research analysts forecast that Sophiris Bio Inc. will post ($0.73) earnings per share for the current year.

Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.